Skip to Content
MilliporeSigma
All Photos(2)

Documents

MKI1MAG-94K

Millipore

MILLIPLEX® Mouse Kidney Injury Magnetic Bead Panel 1 - Toxicity Multiplex Assay

The analytes available for this multiplex kit are: β-2-Microglobulin, IP-10, KIM-1, Renin, TIMP-1, VEGF (for urine samples) or IP-10, KIM-1, Renin, and TIMP-1 (for serum/plasma samples).

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Quality Level

species reactivity

mouse

manufacturer/tradename

Milliplex®

assay range

accuracy: 73-98%
sensitivity: 0.001-0.041 ng/mL
(MinDC+2SD)

standard curve range: 0.001-1 ng/mL
(VEGF)

standard curve range: 0.005-5 ng/mL
(IP-10)

standard curve range: 0.01-15 ng/mL
(KIM-1)

standard curve range: 0.02-25 ng/mL
(TIMP-1)

standard curve range: 0.05-50 ng/mL
(β-2-Microglobulin)

standard curve range: 0.05-50 ng/mL
(Renin)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

General description

The MILLIPLEX® Mouse Kidney Injury Bead Panel 1 contains all the components necessary to measure the following six biomarkers in any combination using Luminex® xMAP® technology: β-2-Microglobulin, IP-10, KIM-1, Renin, TIMP-1, VEGF. The kit uses a 96-well format, contains a lyophilized standard cocktail, two quality controls and can measure up to 38 urine samples in duplicate.

Application

  • Analytes: β-2-Microglobulin, IP-10, KIM-1, Renin TIMP-1, VEGF
  • Recommended Sample type: urine
  • Recommended Sample dilution: 1:25
  • Assay Run Time: overnight
  • Research Category: Toxicity

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Other Notes

Please contact Technical Service for linearity of dilution.
Sensitivity: Please see kit protocol for individual assay sensitivities.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

wgk_germany

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lucía Echevarría et al.
Methods in molecular biology (Clifton, N.J.), 2434, 371-384 (2022-02-26)
Antisense oligonucleotides (ASO) therapeutics hold great promise for the treatment of numerous diseases, and several ASO drugs have now reached market approval, confirming the potential of this approach. However, some candidates have also failed, due to limited biodistribution/uptake and poor
Karima Relizani et al.
Molecular therapy. Nucleic acids, 8, 144-157 (2017-09-18)
Antisense oligonucleotides (AONs) hold promise for therapeutic splice-switching correction in many genetic diseases. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake and sufficient therapeutic efficacy is still difficult to
Karima Relizani et al.
Nucleic acids research, 50(1), 17-34 (2021-12-12)
Tricyclo-DNA (tcDNA) is a conformationally constrained oligonucleotide analog that has demonstrated great therapeutic potential as antisense oligonucleotide (ASO) for several diseases. Like most ASOs in clinical development, tcDNA were modified with phosphorothioate (PS) backbone for therapeutic purposes in order to
Gene Ryan Crislip et al.
Biomolecules, 12(2) (2022-02-26)
BMAL1 is a core mammalian circadian clock transcription factor responsible for the regulation of the expression of thousands of genes. Previously, male skeletal-muscle-specific BMAL1-inducible-knockout (iMS-BMAL1 KO) mice have been described as a model that exhibits an aging-like phenotype with an
Monica Javidnia et al.
Journal of Alzheimer's disease : JAD, 60(2), 461-481 (2017-09-05)
Hyperphosphorylation and aggregation of tau protein is a critical factor in many neurodegenerative diseases. These diseases are increasing in prevalence, and there are currently no cures. Previous work from our group and others has shown that tyrosine kinase inhibitors (TKIs)

Related Content

Multiplex kidney toxicity assays detect nephrotoxicity biomarkers in small samples, minimizing time and costs for toxicity screening.

MILLIPLEX® toxicity assays advance liver, kidney, and genotoxicity research by simultaneously measuring multiple toxicity biomarkers.

Discover the benefits of MILLIPLEX® multiplex assays, based on Luminex® xMAP® multiplex assay technology, that provide consistent, high-quality results and see how these multiplex biomarker Luminex® assays are being used to advance research.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service